Study To Assess Long Term Safety Of Pazopanib

An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients

This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.

Key Inclusion Criteria:

• Participated or completed a GSK sponsored pazopanib study and remains eligible for continued treatment with pazopanib and lapatinib (if on combination therapy).
• Able to understand and provide written informed consent
• Women and men agree to use protocol specific birth control measures

Key Exclusion Criteria:

• The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer
• If you are pregnant or breast feeding
• Your doctor does not think you would be a good candidate for the study
• Poorly controlled high blood pressure
• Subject is unwilling or unable to follow the procedures outlined in the protocol.